Detalhe da pesquisa
1.
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Breast Cancer Res
; 25(1): 112, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37784176
2.
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Expert Rev Anticancer Ther
; 24(6): 397-405, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38642015
3.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Ther Adv Med Oncol
; 15: 17588359231152844, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36743521
4.
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
JCO Precis Oncol
; 7: e2200531, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141549
5.
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Clin Cancer Res
; 29(16): 3092-3100, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265453
6.
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
EBioMedicine
; 86: 104316, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332363